Cardisure is indicated for the treatment of canine congestive heart failure originating from valvular insufficiency or dilated cardiomyopathy (DCM), and may be part of symptomatic management for the preclinical stage of Myxomatous Mitral Valve Disease (MMVD) to delay the onset of clinical symptoms of heart failure.

The medication is commonly used across conditions presenting with systemic or localized discomfort associated with reduced heart function. It helps address symptom clusters that may become intense or disruptive, specifically relieving respiratory distress like chronic coughing and labored breathing, as well as improving physical activity tolerance (such as lethargy and fatigue). A relevant therapeutic application is its use in asymptomatic patients, providing support before overt heart failure signs begin. In situations where patients experience these symptomatic changes, the goal of treatment is to ease the overall symptom burden. “The goal is to support functional stability and contribute to improved comfort during periods of heightened symptoms.” This provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Congestive Heart Failure Signs
Symptom Focus	Chronic Cough, Labored Breathing (Tachypnea), Activity Intolerance
Condition Type	Conditions presenting with systemic or localized discomfort (MMVD, DCM)
Primary Benefit	Provides support that helps ease the overall symptom burden and assists with maintaining functional stability

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) Summary of Product Characteristics

Cardisure (pimobendan) is a veterinary medicinal product strictly for use in dogs with congestive heart failure. Official regulatory documents define clear populations for whom its use is either prohibited or requires special consideration.

Contraindicated Populations

Use is prohibited in dogs with:

• Hypertrophic cardiomyopathies.
• Aortic stenosis or any other condition where increasing cardiac output is not possible or is functionally inappropriate.

Restricted or Special Consideration Use

Specific precautions must be taken for dogs with certain health states or characteristics:

Population Category	Restriction/Status	Regulatory Basis
Severe Hepatic Insufficiency	Use requires particular care (drug is metabolized by the liver).	Precaution
Diabetic Dogs	Blood glucose levels must be carefully monitored.	Precaution
Pregnant/Nursing Bitches	Safety has not been established; use only after a benefit/risk assessment.	Precaution

In summary, Cardisure's use is limited to the canine species and is formally contraindicated in severe obstructive cardiac diseases. Its administration in animals with diabetes, severe liver impairment, or during pregnancy/lactation requires specific veterinary caution and monitoring, as safety has not been fully assessed in these groups.

Interactions with other medicines and products

Official regulatory information for Cardisure (Pimobendan) defines interaction patterns that involve pharmacodynamic attenuation and specific pharmacokinetic constraints related to administration timing and bioavailability.

---

Pharmacodynamic Interaction Constraints

Co-administration with certain classes of cardiac medications is documented to attenuate the positive inotropic effect of Pimobendan. These pharmacodynamic interactions diminish the intended effect of increasing heart contractility.

Interacting Product Category	Official Interaction Statement
Calcium Antagonists (e.g., Verapamil, Diltiazem)	Documented to attenuate the positive inotropic effect.
Beta-Antagonists (e.g., Propranolol)	Documented to attenuate the positive inotropic effect.

No interaction was detected in regulatory studies when Pimobendan was co-administered with the cardiac glycoside Ouabain.

---

Pharmacokinetic and Population Considerations

A critical pharmacokinetic constraint is the interaction with food. The administration of Cardisure must take place approximately one hour before feeding, as simultaneous intake considerably reduces the drug’s absolute bioavailability and, consequently, its systemic exposure. This timing rule is mandatory to ensure adequate absorption.

Additionally, due to the drug's primary clearance occurring via the liver, official documents caution that particular care is required during administration in patients with severe hepatic insufficiency, as this condition suggests a risk of altered drug exposure.

Cardisure's mechanism is anchored by the dual action of its active compound, Pimobendan, which operates through two complementary pharmacological pathways to modulate the physiological dynamics of the cardiovascular system. This combined activity defines its classification as an inodilator.

Calcium Sensitization: Enhanced Cardiac Contractility

This domain covers the drug's unique direct action on the heart muscle's contractile machinery. Pimobendan binds to the protein Troponin C within the cardiac muscle fibers, increasing its sensitivity to existing intracellular calcium ( Ca^2+). This interaction enhances myocardial contractility (positive inotropy) without increasing the demand for oxygen or cellular energy.

Selective PDE III Inhibition: Vasodilation and Reduced Resistance

The second, equally critical domain involves the selective inhibition of the enzyme Phosphodiesterase III ( PDE III), primarily mediated by Pimobendan's active metabolite. By blocking PDE III, the drug prevents the breakdown of the signaling molecule cAMP in vascular smooth muscle cells. This cascade results in the relaxation of both arterial and venous vessels (vasodilation), which reduces the pressure and resistance the heart encounters during pumping (reduced Preload and Afterload).

Administration Scope

Guidelines for Cardisure (Pimobendan) are focused on the precise calculation and timing of its oral administration over a long-term course.

Feature	Guideline
Route of administration	Oral use only.
Dosing schedule	The total daily dose is between 0.2 mg and 0.6 mg of Pimobendan per kilogram (kg) of body weight, with the target preferable dosage being 0.5 mg/kg per day.
Frequency and Timing	The total daily dose must be divided into two portions and administered approximately 12 hours apart (morning and evening).
Timing in relation to meals	Must be given on an empty stomach, at least one hour before feeding (meals), as absorption is reduced when given with feed.

---

Procedural and Population Constraints

Classification	Detail
Preparation requirements	Tablets are scored to allow breaking into halves (and sometimes quarters) to achieve the required, weight-based dosage to the nearest half-tablet increment. Any portion of a divided tablet must be used within 3 days.
Use-context constraints	Accurate body weight determination is mandatory before treatment to ensure correct dosage. Particular care is required when administering to patients with severe hepatic insufficiency, and blood glucose levels should be carefully monitored in diabetic patients.

---

Connection to the overall use protocol:

The administration protocol establishes a fixed twice-daily frequency and a mandatory fasted-state administration to maximize the drug’s delivery and maintain consistent systemic levels. The protocol requires precise weight-based dosage calculation and individual maintenance adjustments, with specific cautions noted for patients having metabolic or organ constraints.

Research evidence / Overview of studies for Cardisure

Evidence for use in Symptomatic Congestive Heart Failure (CHF)

This section summarizes research, primarily large-scale Randomized Controlled Trials (RCTs) and systematic reviews, that explored the medicine's role when used in dogs that had already developed clinical signs of heart failure. Research has explored both heart failure caused by underlying valvular disease and heart failure caused by dilated cardiomyopathy. Studies monitored patient survival time and outcomes related to systemic or functional imbalance when the medicine was used alongside other standard heart failure management protocols.

CHF Secondary to Valvular Insufficiency

Studies examining CHF resulting from myxomatous mitral valve disease (MMVD) included patients presenting with established, visible signs of fluid accumulation or difficulty breathing. Research monitored outcomes related to daily functioning or activity level and tracked changes in survival time within the observed populations. Trials generally reported measurements that were used by regulatory bodies to characterize the medicine’s supportive role in this advanced stage of heart disease, with findings describing patterns observed in the studies related to overall survival. Studies reported measurements of survival time and described patterns in clinical status scores across the populations studied. However, comparative evidence is lacking regarding the medicine's effects when combined with certain modern, multi-drug regimens that were introduced after some of the pivotal trials were completed.

CHF Secondary to Dilated Cardiomyopathy

For heart failure caused by Dilated Cardiomyopathy (DCM), research examined patients already experiencing clinical CHF. These studies monitored endpoints such as overall survival time and outcomes describing episodic or acute changes in clinical condition. Studies report how symptoms evolved in the observed populations and described patterns in the measured clinical status, but the inherently severe nature of DCM in some patient subgroups means that long-term effects are not fully established and data collection on outcomes remains a challenge. Research often focused on the use of the medicine alongside other established drug classes for this condition.

Evidence for use in Preclinical Heart Disease (Asymptomatic Patients)

This area of research utilized large-scale, multi-center, double-blinded, placebo-controlled trials that evaluated the medicine’s use in patients who had not yet developed overt clinical signs of heart failure but showed specific evidence of cardiac enlargement. The primary metric monitored was the time elapsed until a pre-defined composite endpoint was reached, such as the onset of heart failure signs or cardiac-related death.

Preclinical Myxomatous Mitral Valve Disease (MMVD)

The research for this indication focused on asymptomatic dogs with MMVD who met pre-defined criteria for substantial cardiac enlargement (Stage B2). The studies monitored the progression of heart disease over defined time intervals, with the main findings describing patterns observed in the time until the patients experienced the composite outcome of heart failure onset or cardiac death. The research provides observations related to how the disease progressed in the studied populations. Research, however, provides limited insight into patients with MMVD who have heart murmurs but do not meet the specific criteria for cardiac enlargement studied in the major trials, meaning data for certain groups remain insufficient.

Preclinical Dilated Cardiomyopathy (DCM)

Studies exploring DCM in asymptomatic patients were conducted in specific, high-risk breeds, notably Doberman Pinschers, confirmed to have left ventricular dysfunction but no clinical signs. Research examined the time elapsed until the composite endpoint of CHF signs or sudden cardiac events. The primary evidence base for this indication is highly concentrated on one specific breed, meaning results apply only to the populations studied and there is limited information to fully characterize outcomes for other breeds in the preclinical stage.

Long-Term Studies and Follow-up

The initial pivotal trials for the medicine in preclinical disease stages involved follow-up durations that extended over several years. Research monitored short-term symptom changes and also tracked overall survival time across extended periods. These studies help show what has been observed so far regarding the length of time patients remain asymptomatic. However, as is common in chronic disease research, long-term effects are not fully established beyond the conclusion of the initial clinical trial periods, and data for outcomes many years after the initial research are still emerging.

Research Gaps and Uncertainties

This section highlights the main areas where evidence is limited or ongoing. While Cardisure was studied for various heart conditions, comparative evidence is lacking for some of its uses in combination with newer, standard heart failure medications. Evidence quality varies across studies, particularly for older trials involving symptomatic heart failure. Furthermore, the research scope was constrained by limited sample sizes or restricted to specific breeds or stages of disease in certain indications. Therefore, the available research provides context but not individual predictions, and the long-term patterns, safety, and effects in diverse and specific patient groups are not fully established.

Key Studies & References

1. UKPAR - Cardisure (Pimobendan) - Summary of Product Characteristics

Common questions about Cardisure (FAQ)

Q: Is Cardisure a cure, or does it only manage the heart condition?

According to official product information, Cardisure is indicated for the long-term management of the clinical signs associated with congestive heart failure (CHF). Studies have shown associations between the medication and improvements in quality of life and extended survival time. The drug is described as supportive of the circulatory system rather than providing a cure, as heart disease remains a chronic condition.

---

Q: Are the side effects of Cardisure usually mild and temporary?

The most common adverse effects, which include vomiting, diarrhea, lethargy, and anorexia (loss of appetite), are typically observed during the initiation of treatment and are often described as transient (temporary). If a dose-dependent effect, such as an increased heart rate or vomiting, occurs, the official information notes that dose reduction is one option discussed in the regulatory documentation.

---

Q: What does 'contraindication' mean in the context of Cardisure usage?

A contraindication is a term used in official documents to identify a pre-existing medical condition or circumstance that officially restricts the use of a medicine. For Cardisure, specific contraindications are established, including hypertrophic cardiomyopathies and aortic stenosis.

---

Q: Is there any research comparing Cardisure's mechanism to older heart medicines?

Studies summarized in regulatory documents focused on specific pharmacological interactions between pimobendan and other cardiac drugs. For instance, no interaction was detected when pimobendan was used alongside the cardiac glycoside ouabain. Official information also notes that the positive inotropic effect of Cardisure may be attenuated (lessened) if it is co-administered with a β-adrenergic blocker or a calcium channel blocker (other types of heart medicines).

---

Q: What signs might indicate a serious reaction to Cardisure?

Official product information notes that adverse clinical findings reported include the development of elevated kidney or liver enzyme levels or certain cardiac events such as arrhythmias (irregular heartbeats). In cases of overdose, a fast heart rate and vomiting are expected. Any worsening condition or observation of severe effects should be reported to the prescribing professional.

---

Q: Can Cardisure cause changes in a person's weight?

This medication is intended for the treatment of heart failure in dogs. One of the most common adverse reactions reported in the target species is anorexia, which is poor or decreased appetite.

---

Q: How quickly does Cardisure start to take effect after starting treatment?

The medication is rapidly absorbed by the body. Regulatory pharmacokinetics data indicate that the drug typically reaches its highest concentration in the blood within approximately 2 to 4 hours after oral administration. While the drug starts working quickly, visible improvement in clinical signs may not be noticeable for up to a week or more.

---

Q: Does Cardisure have a 'loading' period before maximum benefits are seen?

The official dosing instructions specify a fixed daily amount that is divided into two separate administrations, usually 12 hours apart. No formal loading phase or higher initial dose is described in the regulatory information for the drug. The full clinical benefit, such as increased survival time, is measured over the long-term course of treatment.

---

Q: Is it normal to experience dizziness shortly after starting Cardisure?

Dizziness is not explicitly listed as a side effect in the official product information for the target species. However, other adverse reactions reported include ataxia (a lack of coordinated movement), weakness, and syncope (fainting or collapse).

---

Q: What official information is available regarding Cardisure use in patients with kidney problems?

Official information indicates the drug's effects may be prolonged in patients who have either kidney or liver disease. Additionally, findings of elevated kidney levels (azotemia) have been reported as a potential adverse clinical finding during drug use.

---

Q: Is it possible for a patient to develop a dependency on Cardisure?

The regulatory documents do not mention dependency, addiction, or abuse liability. Pharmacological studies examined the response to repeated administration, noting that it did not result in evidence of tachyphylaxis (a rapid decrease in response to the drug).

---

Q: What should be done if a dose of Cardisure is missed?

The official product information provides regulatory instructions for a missed dose. These instructions state that if a dose is missed, the patient should skip the missed dose and receive the next dose at the regular scheduled time, and not give two doses at the same time to make up for a missed dose.

---

Q: What happens when treatment with Cardisure is stopped?

Because this medicine is prescribed for the long-term management of a chronic condition, the official product information states that consultation with a prescribing professional is required before discontinuing treatment. Discontinuing the medication means the patient will no longer receive the benefits associated with maintaining quality of life and survival time.

---

Q: What is the purpose of the filler ingredients in the Cardisure tablets?

The tablets contain the active substance Pimobendan along with various inactive ingredients, known as excipients. These ingredients are included to give the tablet its flavored characteristic and help ensure the correct pharmaceutical form, integrity, and stability of the medication.

Storage and Handling Requirements

Official regulatory information requires that Cardisure tablets be stored below 30 C. To maintain stability, the tablets must be protected from light, requiring the product to be kept within its original blister packaging and outer carton.

Stability and Child Safety

If a tablet is divided, the unused portion must be returned immediately to the opened blister and used within a period of 3 days. The product must be stored out of the sight and reach of children and the pet being treated to prevent accidental ingestion.

Official Disposal Rules

Unused or expired Cardisure must not be disposed of via household waste or wastewater systems. All disposal must comply with local requirements for pharmaceutical waste. Individuals should consult with a veterinary professional regarding appropriate disposal methods for any unused medication.